RU96119975A - NEW USE OF QUINOLIN-3-CARBOXAMIDE COMPOUNDS - Google Patents
NEW USE OF QUINOLIN-3-CARBOXAMIDE COMPOUNDSInfo
- Publication number
- RU96119975A RU96119975A RU96119975/14A RU96119975A RU96119975A RU 96119975 A RU96119975 A RU 96119975A RU 96119975/14 A RU96119975/14 A RU 96119975/14A RU 96119975 A RU96119975 A RU 96119975A RU 96119975 A RU96119975 A RU 96119975A
- Authority
- RU
- Russia
- Prior art keywords
- attached
- compound
- quinoline
- carboxamide
- hydrogens
- Prior art date
Links
- BLTDCIWCFCUQCB-UHFFFAOYSA-N quinoline-3-carboxamide Chemical class C1=CC=CC2=CC(C(=O)N)=CN=C21 BLTDCIWCFCUQCB-UHFFFAOYSA-N 0.000 title claims 5
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 claims 2
- 229940030999 antipsoriatics Drugs 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 230000002682 anti-psoriatic effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Claims (7)
где (а) _ _ _ _ _ означает, что между атомами, соединенными штриховой линией, существуют две сопряженные двойные связи;
(b) Х1 и Х2 каждый отдельно выбран из атома кислорода или NH9-группы, при этом указанные Х1 и Х2 присоединены к кольцу одинарной связью, когда они присоединены к H7 или Н8, и двойной связью, когда не присоединены к H7 или H8;
(с) H1-9 являются водородами, при условии, что H9 присутствует только в случае, когда по меньшей мере один из Х1 и Х2 является NH9-группой,
(d) Н7 и Н8 являются водородами, присоединенными к различным атомам, выбранным из Х1, Х2 и атома азота в хинолиновом кольце, для изготовления композиции, предназначенной для лечения псориаза или состояний, ассоциированных с псориазом.1. The use of an antipsoriasis compound of quinoline-3-carboxamide having structural formula I, optionally with hydrogen atom substituents designated (H 1-9 ), or a pharmaceutically acceptable salt of said compound
where (a) _ _ _ _ _ means that between the atoms connected by a dashed line, there are two conjugated double bonds;
(b) X 1 and X 2 are each individually selected from an oxygen atom or NH 9 group, wherein said X 1 and X 2 are attached to the ring by a single bond when they are attached to H 7 or H 8 , and by a double bond when not attached to H 7 or H 8 ;
(c) H 1-9 are hydrogens, provided that H 9 is present only when at least one of X 1 and X 2 is an NH 9 group,
(d) H 7 and H 8 are hydrogens attached to various atoms selected from X 1 , X 2 and a nitrogen atom in the quinoline ring to formulate a composition for treating psoriasis or conditions associated with psoriasis.
где (а) _ _ _ _ означает, что между атомами, соединенными штриховой линией, существуют две сопряженные двойные связи,
(b) Х1 и Х2 каждый отдельно выбран из атома кислорода или NH9-группы, при этом указанные Х1 и Х2 присоединены к кольцу одинарной связью, когда они присоединены к Н7 или Н8, и двойной связью, когда они не присоединены к Н7 или Н8,
(с) Н1-9 являются водородами, при условии, что H9 присутствует только в случае, когда по меньшей мере один из Х1 и Х2 является NH9- группой,
(d) Н7 и Н8 являются водородами, которые присоединены к различным атомам, выбранным из Х1 и Х2 и атома азота (N) в хинолиновом кольце, в количестве от 0,01 до 10 мг/кг веса тела, предпочтительно от 0,05 до 1 мг/кг веса тела, от одного раза в день до одного раза в две недели.3. A method for the treatment of psoriasis or conditions associated with psoriasis by administering an effective amount of an antipsoriatic compound, characterized in that quinoline-3-carboxamide of structural formula I is introduced as an antipsoriotic compound, optionally with hydrogen atom substituents designated (H 1-9 )
where (a) _ _ _ _ means that between the atoms connected by a dashed line, there are two conjugated double bonds,
(b) X 1 and X 2 are each individually selected from an oxygen atom or NH 9 group, wherein said X 1 and X 2 are attached to the ring by a single bond when they are attached to H 7 or H 8 , and by a double bond when they not attached to H 7 or H 8 ,
(c) H 1-9 are hydrogens, provided that H 9 is present only when at least one of X 1 and X 2 is an NH 9 group,
(d) H 7 and H 8 are hydrogens that are attached to various atoms selected from X 1 and X 2 and a nitrogen atom (N) in the quinoline ring, in an amount of from 0.01 to 10 mg / kg body weight, preferably from 0.05 to 1 mg / kg body weight, from once a day to once every two weeks.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9400810-9 | 1994-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU96119975A true RU96119975A (en) | 1999-01-27 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU95121639A (en) | AZA Cyclohexappeptide Compounds | |
| KR880011125A (en) | Heterocyclic Compounds, Methods for Making and Uses thereof | |
| EP0034473A3 (en) | Substituted imidazoles, their preparation, pharmaceutical compositions containing the same and their use in therapy | |
| CA2380414A1 (en) | Method of cancer treatment | |
| RU96107392A (en) | PHOTOSENSIBILIZERS | |
| RU97116161A (en) | NITROGEN OXIDE SYNTHASE INHIBITORS BASED ON MERCAPTO AND SELENIUM DERIVATIVES | |
| ATE103585T1 (en) | POLYAMINE DERIVATIVES AS ANTINEOPLASTIC AGENTS. | |
| SE9400810D0 (en) | New use of quinoline-3-carboxamide compounds | |
| IL100484A0 (en) | Therapeutic benzazepine compounds | |
| SE9400809D0 (en) | New use of quinoline-3-carboxamide compounds | |
| UA41329C2 (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HEART RATE DISORDERS IN LARGE MAMMALS AND HUMANS, DERIVATIVES OF 3-PHENYLSULPHONYL-3,7-DIAZ | |
| RU96119975A (en) | NEW USE OF QUINOLIN-3-CARBOXAMIDE COMPOUNDS | |
| BG106180A (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| DK0738712T3 (en) | Substituted indenoylguanidines with antiarrhythmic cardioprotective effect | |
| WO1996032944B1 (en) | Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor | |
| KR880005134A (en) | Indolo-pyrazino-benzodiazeamine derivatives | |
| KR940000443A (en) | Pyridyl-1,2,5-oxadiazolecarboxamide-2-oxide | |
| KR950031072A (en) | Pharmaceuticals containing the new 3-benzoyl-3, 7-diazabicyclo [3, 3, 1] nonan-compounds | |
| RU96119990A (en) | NEW USE OF QUINOLIN-3-CARBOXAMIDE COMPOUNDS | |
| KR910016331A (en) | Ischemic Disease Drug | |
| KR950702830A (en) | METHODS OF TREATING PSORIASIS EMPLOYING SUBSTITUTED AZASPIRANES | |
| KR900012918A (en) | Calcium antagonists | |
| IE790108L (en) | Isoquinoline compounds | |
| KR910006290A (en) | Pyrimidoindole derivatives and preparation method thereof | |
| RU2002133099A (en) | APPLICATION OF TALIPORPHINE OR ITS DERIVATIVES IN THE TREATMENT OF HEART DISEASES AND OBTAINING THESE COMPOUNDS |